ProKidney Corp. reported Tuesday a $16.5 million second-quarter loss as the Winston-Salem biopharmaceutical manufacturer pursues a breakthrough drug therapy for patients experiencing advanced chronic kidney disease.

ProKidney, based at 3929 Westpoint Blvd. Suite G, is a late clinical-stage cellular therapeutics company focused on chronic kidney disease.

The second-quarter loss is up from $12.5 million a year ago.

There was an earnings loss of 13 cents per share, compared with a loss of 16 cents a year ago.

ProKidney listed $221,000 in revenue during the second quarter — the second time it has reported revenue as a publicly traded company after $239,000 in the first quarter.

The company has expanded from 80 to more than 200 employees over the past three years. The company said it is hi

See Full Page